Orexin Receptor Antagonist Drug Class List

Drugs in Drug Class: Orexin Receptor Antagonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-002	Apr 7, 2022		RX	Yes	Yes
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No			Y	Y
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-002	Apr 7, 2022		RX	Yes	Yes			Y	Y

Orexin Receptor Antagonist Market Dynamics and Patent Landscape (DORA, FDA Exclusivity, Orange Book, Generics vs Brands)

Last updated: July 8, 2026

Orexin receptor antagonists are a concentrated sleep portfolio driven by a small set of branded products and an increasing share of “next-generation” reformulations and method-of-use filings. Patent risk is dominated by (i) composition-of-matter coverage tied to orexin receptor antagonists, (ii) formulation and manufacturing-process patents around dosing forms and release behavior, and (iii) regulatory exclusivity that can delay first generic entry even where patents are not asserted.

What patents protect orexin receptor antagonists (DORA) and how broad is the estate by active ingredient?

Answer: Protection typically clusters into three layers: compound/formulation patents (composition-of-matter and compositions), method-of-use patents (insomnia subpopulations, dosing regimens, and comorbid symptom management), and device/process or manufacturing patents (crystallinity, polymorphs, particle size, stability). The strongest estates are those with both early filing compound patents and later-life cycle formulation or solid-state patents.

Which orexin receptor antagonists are in scope for patent landscape mapping?

Orexin receptor antagonists marketed in the US and commonly analyzed in exclusivity and patent charts include dual orexin receptor antagonists (DORA) and orexin receptor antagonists (ORA) such as:

• Suvorexant (DORA)
• Lemborexant (DORA)
• Daridorexant (DORA)

How do the patent stacks differ between DORA assets?

• Compound patents: Usually early filings with expiration dates that set the outer boundary for generic/barrier entry absent successful patent challenges.
• Formulation patents: Often filed later and can extend effective exclusivity by blocking “launch-ready” manufacturing variants, especially when they cover specific tablet formulations, coatings, or release characteristics.
• Method-of-use patents: More common where label differentiation exists (dose titration, geriatric dosing, insomnia disorder subsets). These are the most likely to be asserted in litigation targeting “skinny-label” design-arounds.

What patent types most frequently trigger Paragraph IV challenges?

1. Orange Book-listed formulation or solid-state patents tied to a specific dosage strength.
2. Process patents that control crystallinity/polymorphs or stability.
3. Method-of-use patents that correspond to FDA-approved dosing instructions that generics may still rely on for labeling.

When do orexin receptor antagonist patents expire and when do brands lose exclusivity?

Answer: Generic launch timing is controlled by the later of (i) statutory patent expiration for relevant Orange Book patents and (ii) regulatory exclusivity windows (new chemical entity and related exclusivity). In practice, DORA assets often face staggered expiration by patent family and by dosage strength, producing a “cliff” that can be softened by later-life cycle patents.

How to read expiration cliffs for DORA assets

For each DORA brand, the practical launch timeline is:

• Patent expiration: earliest active ingredient patent expiration for the compound plus any later-expiring formulation/process patents listed in the Orange Book for the approved NDA.
• Orphan/other exclusivity (if any): not typically the key driver for DORA, but any applicable exclusivity extends the window beyond patent life.
• Pediatric exclusivity: can extend by 6 months if qualifying studies are submitted and granted.
• Dosing strength granularity: separate Orange Book listings by strength can create staggered entry.

What the exclusivity timing means for market entry

• If a generic candidate files with a certification that attacks only some patents, the unchallenged patents can still block approval.
• If multiple Orange Book patents cover the same dosage form, the generic must either prevail in litigation or secure a settlement that permits launch.

What is the Orange Book status of suvorexant, lemborexant, and daridorexant?

Answer: Orange Book status drives whether a generic can obtain FDA approval. For DORA assets, the Orange Book typically includes both drug substance and drug product patents, with formulation and solid-state patents listed for each dosage form/strength.

Orange Book listing patterns for DORA tablets

• Multiple drug product patents track formulation composition, tablet manufacturing, and/or release/quality attributes.
• Drug substance patents track crystallinity/polymorph control, specific chemical intermediates, or specific salt forms if used in the marketed product.
• Some method-of-use patents are not Orange Book listed; they appear in litigation against label/dosing claims.

How Orange Book status affects Paragraph IV strategy

• A Paragraph IV filer benefits most by attacking the latest-expiring drug product patents.
• If only older drug substance patents are attacked, an unchallenged latest drug product patent can block approval even after litigation outcomes.

Which companies are challenging orexin receptor antagonist patents through Paragraph IV AND what does settlement typically require?

Answer: Paragraph IV filings are common for major insomnia brands. For DORA, challenges usually focus on the strongest late-expiring formulation or process patents and seek “at-risk” approval contingent on litigation outcomes.

What a typical Paragraph IV settlement structure looks like

Settlements in high-stakes insomnia portfolios tend to include:

• Launch date agreement (often tied to a specific patent expiration).
• Design-around constraints (to avoid literal infringement).
• Forbearance or dismissal language in exchange for a delayed entry.
• Compensation can occur through cash, supply, or other commercial agreements, with terms varying by case.

Patent scope that often constrains generic design-around

• Specific crystal forms and their manufacturing conditions.
• Specific tablet excipient systems or coating systems.
• Stability and storage behavior claims tied to the formulation.

How strong is the patent estate for orexin receptor antagonists and what parts are most vulnerable?

Answer: Overall estate strength is driven by the number of Orange Book patents per NDA and the presence of multiple life-cycle patents that are both (i) late-expiring and (ii) tied to manufacturable claims. Vulnerabilities arise when late patents cover properties that are not required for FDA approval or when claim scope can be designed around by alternative polymorphs/formulations.

Strength indicators used in DORA patent assessments

• Count of Orange Book patents per NDA (higher count usually increases blocking power).
• Share of late-expiring drug product patents (delays at-risk entry).
• Whether claims are tied to specific manufacturing steps (process patents can be hard to invalidate quickly).
• History of litigation outcomes (invalidation is rare unless claim scope is narrow and prior art is strong).

Common invalidity angles for DORA formulation/process claims

• Lack of novelty for polymorph/crystal claims if prior art discloses the same solid form.
• Obviousness for particle size or excipient selection if the selected range is predictable.
• Indefiniteness where manufacturing parameters or testing thresholds are not clearly defined.

What formulations are protected by orexin receptor antagonist patents (solid-state, polymorph, tablet composition)?

Answer: DORA formulation protection most often targets solid-state forms and tablet manufacturing. This can include polymorph/crystal form patents and tablet composition/manufacturing patents intended to lock in the marketed product’s critical quality attributes.

Solid-state and polymorph coverage

Typical claim strategies:

• Crystal form identity defined by XRD/solid-state characterization.
• Procedures for producing and isolating the crystal form.
• Stability claims linked to storage conditions and changes in solid-state behavior.

Tablet formulation and excipient system coverage

Typical claim strategies:

• Tablet composition within specific ranges for binders/disintegrants/lubricants.
• Film-coating compositions and coating weights.
• Processing parameters tied to granulation, compression, and drying.

Manufacturing process patents

Typical claim strategies:

• Controlled crystallization conditions.
• Drying or milling conditions that preserve or produce the desired solid form.
• Defined impurity profiles or acceptance criteria.

What method-of-use patents exist for orexin receptor antagonists and what dosing/regimen claims matter for generics?

Answer: Method-of-use patents can restrict label design and can be used to prevent generics from marketing within certain dosing instructions. They matter even where a generic can obtain approval based on composition/formulation defenses.

How method-of-use patents show up in litigation

• Allegations that a generic label induces infringement of claimed dosing regimens.
• Claims that target patient populations, such as elderly dosing, sleep onset vs sleep maintenance indications, or insomnia with specific comorbid patterns.

What design-around usually looks like

• Label carve-outs, but generic labeling must still remain FDA-compliant.
• Avoidance of specific dose titration schedules or specific timing instructions tied to the method-of-use claims.

How do orexin receptor antagonists compare on market dynamics (pricing, uptake, channel strategy)?

Answer: The DORA market is competitive on efficacy/safety perceptions, with payer and channel strategy shaping share. Brand persistence is supported by formulary position, contracting, and patient continuity, while generic entry typically triggers rapid price compression on covered products once barriers are cleared.

Key market drivers

• Switching behavior: from traditional hypnotics and sedatives to DORA classes where tolerability and daytime effects are emphasized.
• Formulary placement: managed care decisions can accelerate or slow uptake.
• Special populations: geriatric patients and patients with comorbidities can change prescribing patterns and create a label tail that method-of-use patents may target.

Revenue exposure to patent cliffs

DORA revenue is exposed to:

• “Single product cliffs” if the latest Orange Book patents are blocked for a short period.
• “Multiple product cliffs” where successive strengths or formulation patents expire on different dates.

What generic entry risks exist for orexin receptor antagonists (at-risk launches, FDA approval timing, litigation outcomes)?

Answer: Generic entry risk is highest when:

• The generic challenges multiple late-expiring patents but litigation timeline allows an approval milestone.
• Patent settlements permit launch soon after a defined cutoff date.
• The generic can demonstrate design-around for solid-state/process claims while still aligning with label dosing instructions.

At-risk launch versus settlement entry

• At-risk: requires confidence in invalidation or non-infringement, often expensive.
• Settlement: reduces litigation risk but can price in entry delay, controlling market supply.

Regulatory dependency

Even where the certification strategy clears a path to approval, any unresolved blocking patent can delay final approval depending on the Orange Book listing status and court outcomes.

What patent litigation affects orexin receptor antagonist brands (injunction risk, scope, timeline)?

Answer: For DORA brands, litigation typically determines whether the generic can market at launch. Outcomes often hinge on claim construction for solid-state/process patents and on whether label-based method-of-use claims are sufficiently alleged for infringement.

Litigation timeline mechanics that matter

• Early case stages often settle on schedule rather than complete merits due to injunction leverage.
• Claim construction can quickly narrow or expand infringer risk depending on how courts interpret technical claim terms.

Injunction exposure

• Injunction risk is elevated if the asserted patents are non-overlapping and cover the commercially manufactured product.
• If the generic cannot plausibly design around formulation/process claims, a settlement becomes more likely.

What biosimilar risk exists for orexin receptor antagonists?

Answer: Biosimilar risk is not applicable. Orexin receptor antagonists are small molecules, not biologics.

How does the orexin receptor antagonist competitive landscape shape patent filing and lifecycle strategy?

Answer: The DORA competitive field uses lifecycle patents to preserve commercial share:

• Reformulations (solid-state/manufacturing and tablet composition).
• Controlled release variants (where available).
• Method-of-use or dosing regimen refinement tied to post-approval prescribing patterns.

Competitive patent filing patterns

• Later filings extend beyond the earliest composition patents.
• Claim drafting emphasizes manufacturability constraints to prevent easy design-around.

Key Takeaways

• Orexin receptor antagonists rely on layered IP: compound/formulation patents plus method-of-use and manufacturing/process claims.
• Launch timing is driven by the Orange Book drug product and process patent stack, with later-life cycle patents often controlling effective exclusivity.
• Paragraph IV challenges in DORA typically target late-expiring formulation or solid-state/process patents that block “launch-ready” manufacturing and can be difficult to design around.
• Market dynamics favor brands through formulary position and patient continuity; generic entry tends to produce rapid price compression after barriers are cleared.
• Biosimilar risk is not applicable for these small-molecule DORAs.

FAQs

1) What is the typical number of Orange Book patents for each DORA tablet NDA and why does it matter?
Orange Book patent counts usually include multiple drug product and drug substance listings; higher counts increase the probability that at least one patent blocks approval absent litigation or settlement.

2) Do DORA method-of-use patents prevent FDA approval or only marketing?
They primarily constrain marketing through infringement allegations tied to label/dosing instructions; approval can still occur depending on how the Orange Book patents and certifications resolve.

3) Which is harder to design around for DORA generics: polymorph/solid-state or tablet composition claims?
Solid-state and process claims are often harder because they can require matching the same crystal form produced under controlled conditions and tied to stability.

4) What settlement triggers are common in insomnia brand generic cases?
Settlement triggers are usually launch-date commitments tied to patent expirations and often include label/design-around constraints.

5) Can a generic avoid DORA patent infringement by switching excipients?
If excipient substitutions fall outside claim ranges or if the formulation claims require specific excipient systems, substitution can be a route. If claims are broader (function-based or range-based), design-around becomes constrained.

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book).
2. U.S. Food and Drug Administration. Drug Approval Reports and New Drug Therapy Approvals (Drug approvals and exclusivity context).
3. U.S. Patent Act, 35 U.S.C. § 271 (Infringement; label induced infringement context).
4. FDA. Hatch-Waxman Act and 21 U.S.C. § 355(j) (Paragraph IV and ANDA framework).